AN2 Therapeutics Inc (ANTX)
2.32
+0.04
(+1.75%)
USD |
NASDAQ |
Apr 26, 16:00
2.32
0.00 (0.00%)
Pre-Market: 20:00
AN2 Therapeutics Shareholders Equity (Quarterly): 124.70M for Dec. 31, 2023
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 124.70M |
| September 30, 2023 | 138.97M |
| June 30, 2023 | 87.76M |
| March 31, 2023 | 82.52M |
| December 31, 2022 | 95.37M |
| Date | Value |
|---|---|
| September 30, 2022 | 105.57M |
| June 30, 2022 | 115.86M |
| March 31, 2022 | 115.41M |
| December 31, 2021 | 61.91M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
61.91M
Minimum
Dec 2021
138.97M
Maximum
Sep 2023
103.12M
Average
105.57M
Median
Sep 2022
Shareholders Equity (Quarterly) Benchmarks
| Gilead Sciences Inc | 22.83B |
| QuidelOrtho Corp | 5.006B |
| CymaBay Therapeutics Inc (DELISTED) | 292.26M |
| Insmed Inc | -331.92M |
| Revance Therapeutics Inc | -151.60M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 138.74M |
| Total Liabilities (Quarterly) | 14.04M |